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Background: PSA-directed prostate cancer screening leads to a high rate of false positive identifications and an
unnecessary biopsy burden. Epigenetic biomarkers have proven useful, exhibiting frequent and abundant
inactivation of tumor suppressor genes through such mechanisms. An epigenetic, multiplex PCR test for prostate
cancer diagnosis could provide physicians with better tools to help their patients. Biomarkers like GSTP1, APC and
RASSF1 have demonstrated involvement with prostate cancer, with the latter two genes playing prominent roles in
the field effect. The epigenetic states of these genes can be used to assess the likelihood of cancer presence or
absence.
Results: An initial test cohort of 30 prostate cancer-positive samples and 12 cancer-negative samples was used as
basis for the development and optimization of an epigenetic multiplex assay based on the GSTP1, APC and RASSF1
genes, using methylation specific PCR (MSP). The effect of prostate needle core biopsy sample volume and age of
formalin-fixed paraffin-embedded (FFPE) samples was evaluated on an independent follow-up cohort of 51 cancer-
positive patients. Multiplexing affects copy number calculations in a consistent way per assay. Methylation ratios are
therefore altered compared to the respective singleplex assays, but the correlation with patient outcome remains
equivalent. In addition, tissue-biopsy samples as small as 20 μm can be used to detect methylation in a reliable
manner. The age of FFPE-samples does have a negative impact on DNA quality and quantity.
Conclusions: The developed multiplex assay appears functionally similar to individual singleplex assays, with the
benefit of lower tissue requirements, lower cost and decreased signal variation. This assay can be applied to small
biopsy specimens, down to 20 microns, widening clinical applicability. Increasing the sample volume can
compensate the loss of DNA quality and quantity in older samples.
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In the USA, over 70% of the annually ~1,000,000 per-
formed biopsies for prostate cancer suspicion result in a
cancer-free diagnosis [1–4], with screening programs typ-
ically based on serum PSA levels [5,6]. Due to the limited
performance of this marker in terms of suboptimal sensi-
tivity and specificity, there have been recommendations
against the utilization of serum PSA levels for prostate
cancer screening [7–9]. Several alternatives are actively
being explored for prostate cancer screening and detection.* Correspondence: jepstein@jhmi.edu
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distribution, and reproduction in any mediumThis report emphasizes one particular biomarker strategy,
i.e. DNA methylation of key gene promoter regions. DNA
hypermethylation is an epigenetic change that locks genes
in a silent, non-expressed state [10]. Such changes occur
both during normal development and during oncogenic
processes [11,12]. In cancer, DNA methylation is both an
abundant and frequent event, leading to the functional loss
of key tumor suppressor genes [13]. Through the progres-
sive accumulation of aberrant methylation during oncogen-
esis, epigenetic changes can occur in precancerous lesions
or at some distance of the actual tumor focus, a
phenomenon termed field effect [14]. The latter could be
an important advantage to overcome suboptimal biopsy
localization and false negative findings due to tissue core
sampling errors [15,16].tral Ltd. This is an Open Access article distributed under the terms of the
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curate assay is of paramount importance. In addition,
from the clinical point of view, the assay should be able
to test readily available samples with a range of quantity
and quality. When a diagnostic assay consists of several
subtests, e.g. a panel of several biomarkers, these can,
potentially, be run together in a multiplexed fashion. Al-
though a multiplex assay minimizes sample volume
requirements and specimen handling, and the associated
operator-related and technical errors, it is important to
verify that the generated output reaches the same stan-
dards of accuracy and reliability, compared to the indi-
vidual singleplex biomarker versions.
The current study evaluates a multiplex assay for pros-
tate cancer detection. To reduce the number of false posi-
tives and subsequent unnecessary (repeat) biopsies due to
a lack of PSA-specificity and spurious extraction of biop-
sies cores [15–17], a confirmatory, epigenetic test can be
run on previously collected prostate tissue biopsies [2,18].
The available samples for epigenetic testing are typically
formalin-fixed paraffin-embedded (FFPE) samples used
for histopathological analysis and then routinely archived.
The methylation status of a panel of genes associated with
prostate cancer can be determined on a few sections of
such archived tissue blocks. In the present report, a diag-
nostic tissue-based test for prostate cancer presence con-
sists of the epigenetic statuses of 3 genes, i.e. GSTP1, APC
and RASSF1 [19], in addition to one control gene, ACTB,
used to quantitate amplifiable DNA.
Results and discussion
Multiplexing affects copy numbers
Thirty cancer positive tissue samples and 12 controls from
cancer-free individuals were analyzed with 4 singleplex
assays versus 1 multiplex assay. Samples are typically split
into 2 equal aliquots to assure output. The control gene
ACTB was used as a rough estimate of input DNA quan-
tity and quality. The ratio of the ACTB copies in both
replicates ranged from .73 to 1.17 (one outlier of 1.42
removed) for the multiplex assay and from .74 to 1.19 for
the singleplex assay. The medians of these ratios were
close to 1 for both the singleplex and multiplex assays, i.e.
1.01 and 1 respectively, as could typically be expected for
a distribution of intra-run noise. Moreover, the 2 equal ali-
quots generated similar output in terms of ACTB copy
numbers for both the singleplex and multiplex assays sep-
arately (p-value = .33 & .24 for the multiplex and single-
plex assay respectively; Mann–Whitney paired sample
test). Hence, copy numbers from both aliquots were aver-
aged in all subsequent analyses.
ACTB copy numbers were significantly higher for
the multiplex assay compared to the singleplex assay
(p-value = 4.5e-13; Mann–Whitney paired sample test),
exhibiting a median 1.51-fold copy number increase(range: 1.23–1.73; Figure 1A & B). Similarly, this ef-
fect was very pronounced for the APC methylation
specific assay (Figure 1A & C), with a median copy number
increase of 4.19-fold over the singleplex (p-value=2.7e-08),
while the same effect was less conspicuous for
RASSF1 (p-value = 3.0e-06) and only marginally visible
for GSTP1 (p-value= .00705), which exhibited a median
increase of 1.48-fold and 1.08-fold for matched samples,
respectively (Figure 1A, D & E).
Finally, by fitting a linear model, the copy number
changes introduced through assay multiplexing can be
predicted. Because no template controls yielded 0 copies
for all multiplex and singleplex assays, the model was
generated including the origin. In line with the median
increases, the linear regression yielded amplification fac-
tors of 1.57, 1.19, 4.13 and 1.25 for the ACTB, GSTP1,
APC and RASSF1 assays respectively (Figures 1B–1E).
In conclusion, multiplexing three methylation specific
assays together with the ACTB control assay resulted in
differences in the individual analytical readouts, without
affecting the stability, as indicated by the consistently
high R-square values for the linear models (Figure 1B–E).
These changes were most likely linked through the differ-
ent sensitivity of the fluorophores that are used to separ-
ate the signals of the individual assays. This is best
evidenced by the less pronounced copy number changes
for GSTP1, which is assessed with the same fluorophore
in both the singleplex and the multiplex setup (Add-
itional file 1: Table S1). Therefore, analytical cutoffs for
methylation levels will need to be determined independ-
ently for singleplex and multiplex assays.
Methylation test performance indications
Q-MSP methylation results are most often reported as a
ratio of methylated copies of the target gene divided by
the copy number of a control gene, typically ACTB, and
multiplied by 1000 for convenience. As expected from the
copy number changes occurring due to multiplexing, the
ratios of the multiplexed GSTP1 assay were significantly
lower than the singleplex version (p-value= 3.3e-06;
Mann–Whitney paired sample test), while the reverse was
true for APC (p-value= 2.9e-08). Since the effect of multi-
plexing on the copy numbers of both RASSF1 and ACTB
was fairly similar, the RASSF1 ratios were not altered sig-
nificantly (p= .96).
In this limited assay development cohort, consisting of
actual tumor samples and non-cancerous controls,
methylated GSTP1 copies were observed in all cases, but
none of the controls, leading towards a perfect classifica-
tion and test performance for both the multiplex and
singleplex assays (Figure 1F, Additional file 1: Figure S1).
As could be expected, multiplexing the APC assay intro-
duced an upward shift of the optimal APC cutoff ratio
to separate cases from controls, in line with the general
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Figure 1 Output characteristics of the all-in-one multiplex assay versus 4 singleplex assays. (A) Relative copy number changes for the
individual assays for paired samples presented as the ratio of the multiplex over the singleplex copy numbers. Dot plots for the paired copy
numbers of ACTB (B), APC (C), GSTP1 (D) and RASSF1 (E) for the multiplex assay (y-axis) versus the singleplex assay (x-axis). The gray line represents
identity, i.e. equal result for both versions of the assay, while the black, dashed line represents the median signal change obtained from the
transition of a singleplex to a multiplex assay. The greater the angle between both lines, the higher the increase. The results from the linear fit are
shown with the black, full line. The quality of the fit is represented by the adjusted R2-values. (F) Phi or Matthews correlation coefficient (MCC) in
function of the methylation ratio that is used as a cutoff. The maximal value for MCC is shown as a circle, for each individual assay. Shifts due to
the transition of singleplex to multiplex, between the optimal cutoffs, identified here through maximal correlation, can be observed for each
assay separately.
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timal cutoff ratio remained similar, although with a
slight decrease, for the multiplexed RASSF1 assay. Due
to the predictability and stability of these events, the
small decrease of Phi, or Matthews correlation coeffi-
cient (MCC), a preferred substitute over test accuracy
for small, unbalanced populations [20], is most likelydue to random events, rather than being a consistent
error introduced through multiplexing. Indeed, the max-
imum Phi obtained equals .72 for the multiplex APC
versus .78 for the singleplex APC assay, and .42 versus
.56 for the multiplex and singleplex RASSF1 assays
(Figure 1F). ROC-curves (Additional file 1: Figure S1) for
all the assays confirm these trends, although these are only
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ple size and inadequate constitution of this assay develop-
ment cohort.
In conclusion, multiplexing the GSTP1, APC and
RASSF1 methylation assays does not appear to have an
adverse effect on detecting cancer accurately, especially
when all 3 assay’ results are considered as a whole. Mul-
tiplexing and the use of different fluorophores do affect
the copy numbers of the individual assays, leading to
altered ratios and classification cutoffs. Thus, analytical
cutoffs for optimal sensitivity and specificity are only
valid for either the singleplex or multiplex diagnostic
assay. Although multiplexing did not change the final
tissue sample outcome for GSTP1, the correlation be-
tween methylation status and outcome did slightly de-
crease for APC and RASSF1. Since there does seem to
be a consistent trend in the way multiplexing affects a
particular singleplex assay (Figure 1), the changes in
MCC for APC and RASSF1 are likely random events due
to the small sample size of this cohort.
Tissue minimization and sample age
Several reasons could warrant the transition of multiple
diagnostic singleplex assays to one multiplex product.
Minimizing the potential operator and technical errors
has already been highlighted. The need for sufficient sam-
ple quantity is an additional factor that should be taken
into account. In this light, Q-MSP results of the multiplex
assay were tested in decreasing amounts of biopsy sec-
tions. To this end, biopsies consisting of 10, 20 and 40 μm
from FFPE tissue blocks from the minimization cohort
were tested and compared.
Two outliers, that yielded copy number values for
RASSF1 over 10-fold of the maximally obtained ACTB
copy number, were removed from the analysis. For non-
descriptive analyses, samples from 2005 and 2006 are
grouped and considered old samples, i.e. 5 years or more
since fixation and archiving. Samples from 2011 are con-
sidered new, i.e. recently fixated and archived.
A comparison of relative DNA quantity and quality
can be made between all these biopsy samples taking
into account the tissue volume and the sample age
(Figure 2A). The effect of the sample age is quite obvi-
ous, with older samples from 2005 and 2006 clearly
showing lower relative DNA yields, measured as ACTB
copies per micron. The effect of the original sample vol-
ume on the relative DNA yield appears to be minor, al-
though a small increase for larger volumes can be
observed. The conditions for an analysis of variance are
not strictly fulfilled, however, this test is used to further
elucidate the relative contributions of sample age and
sample volume. A linear model can be fit to the relative
ACTB copy numbers, or the log of the relative ACTB
copy numbers, since the latter fits the normalityassumptions better. Both models indicate consistent
results, with the age of samples being the only significant
factor (p = 3.9e-11; ANOVA).
In conclusion, the age of samples has a significant im-
pact on the DNA quantity and quality. Increased sample
volume is likely to be beneficial to recover more DNA,
which could be of noteworthy importance for conduct-
ing the assay on older samples. Although larger sample
volumes do seem to result in a higher DNA extraction
efficiency (Figure 2A), this does not appear to be
significant.
Sample usability and DNA detectability
With lower amounts of sample input and sample ageing,
the likelihood increases that signals will be indistinguish-
able from noise and therefore lost. Assessing the status
of the control gene first, 11 samples failed to show any
ACTB copies in either one of the aliquots, of which 10
are classified as older samples (8 from 2005). In addition,
6 of these samples are from 10-micron specimens, 4
from 20-micron biopsies and only 1 from a 40-micron
biopsy. Obviously, higher sample quantity and more re-
cent sample fixation, minimize the chance of producing
an undetectable ACTB signal. In addition, the majority
of the undetectable signals occur in only one of the
replicates. When the averaged aliquots are considered
instead, only 5 older samples did not contain any ACTB
copies, of which three were 20-micron samples and two
were 10-micron samples. Figure 2B illustrates the frac-
tion of detectable samples as a function of the ACTB
copy number. All findings concerning trends for DNA
yield relative to sample age and sample quantity are
reinforced.
The minimal DNA quantity, in terms of ACTB copies,
that results reliably, i.e. more than 0 copies for both
replicates, in the detection of methylated copies of
GSTP1, APC and RASSF1 equals to 51, 27 and 63 re-
spectively. A cutoff on ACTB of 50 to 100 copies should
result in the reliable detection of methylation of all three
genes. Below the cutoff of 63, not detecting methylated
copies of either assay could be either due to a true lack
of methylation or due to insufficient qualitative DNA.
From Figure 2B it can be derived that for recent sam-
ples, 20-micron is sufficient, with no sample loss due to
undetectable ACTB copies. For samples up to 5 years of
age, a loss can be expected almost regardless of the
tissue volume. Allowing a maximal sample loss of 20%,
40-micron samples pose no problem, while 20-micron
samples become borderline usable.
Effects of quantity and quality restrictions
Probably the most important characteristic of any clin-
ical test is the final sample classification, i.e. whether
methylated copies of a test gene can be detected in the
A10 µm 20 µm 40 µm
B
Figure 2 Reliably measuring DNA input quality and quantity. (A) Relative DNA yield in terms of ACTB copy numbers per micron of biopsy
tissue, stratified by age and sample quantity groups. Outliers, i.e. data points exceeding 1.5 times the respective interquartile distances, are not
represented. (B) Relative amount of detectable samples, in terms of possessing a minimum of ACTB copies, as a function of the total amount of
ACTB. Gray horizontal lines represent possible, minimal cutoffs to assure sufficient DNA quantity and quality, set here at 50 and 100 ACTB copies.
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the amount of input material and the possibility of detect-
ing methylation signals. For the tissue minimization study,
the methylation ratio was determined using three,
matched, biopsy-volume levels, i.e. 10, 20 and 40 microns.
If methylation was observed in any of these, the biopsy
was considered methylated. Methylation can be missed
due to a lack of input material or due to the random sam-
pling technique of the biopsy tissue relative to the tumor’s
location within the prostate gland. The random combin-
ation of tissue block sections having variable methylation
levels could also impact detection.
Samples were considered for subsequent analyses
when the minimal DNA quantity and quality require-
ments were met, i.e. when ACTB exceeded 63 copies, as
determined above. Table 1 lists the frequencies of accur-
ately analyzable samples in terms of the ability to detect
sufficient DNA and methylation signals, relative to the
sample volume and age. More recent and larger volume
samples clearly outperformed older, smaller ones. Espe-
cially the 10-micron samples suffered from insufficient
input material in terms of ACTB copies. If sufficient
DNA can be detected, the methylation signal was picked
up reliably for each assay, down to a volume as low as
20 μm (Table 1).
The loss of methylation signals in the 40-micron sam-
ples was most likely due to the randomness of the com-
bination of tissue slices and the presence of cancer foci
within the biopsy tissue tested in the assay. Indeed,
methylation of either assay did not exceed the respective
critical threshold for 4 of the recent, 40-micron samples,
although results of the 10- or 20-micron samples indi-
cated methylation. However, all four samples possess
ample quantities of ACTB, i.e. with a minimum of 680copies. Therefore, the lack of sufficient, high quality
DNA was unlikely to explain the small amount of sam-
ples where methylation was not observed for any epigen-
etic assay, although at least one positive signal was
expected.
Table 1 also lists the relative amount of samples that
were accurately analyzable and gives the correct sample
outcome as a function of age and volume. Such samples
possessed a minimal amount of DNA that appeared to
be sufficient for downstream Q-MSP analyses, and in
these, methylation was detected reliably. Older, up to
5 years, 20-micron samples seem to be at the current
technical limit for methylation analyses.
Conclusions
Screening of prostate cancer suffers from a lack of speci-
ficity, identifying many false positives, mainly through
the use of routine PSA screening and follow-up biopsy
tissue analysis [21]. Men with elevated PSA-levels but
negative biopsies will typically be re-evaluated and may
be rebiopsied, although this has been proven unneces-
sary for the vast majority [22,23]. Epigenetics, more spe-
cifically DNA methylation, has been postulated to aid
the diagnostic process. Because the presence of cancer
cells missed by standard histopathology can be detected
through DNA methylation [14], a confirmatory epigen-
etic assay can reinforce a negative finding or indicate the
need for a rebiopsy in men with an initial negative bi-
opsy [2].
DNA methylation plays a role in gene silencing and
acts as a powerful biomarker by repressing tumor sup-
pressor genes during oncogenesis [24]. The functional
loss of key genes in normal cells is progressive in nature,
accumulating deregulating oncogenic hits and eventually
Table 1 Relative sample amount for which methylation can be determined as function of quantity and age
tissue
biopsy
volume
sample
age
# samples
(% correctly
analyzable)
sufficient
input
DNA
methylated copies of
GSTP1 APC RASSF1
10 μm >= 5 years 45 (60%) 67% 81% 81% 48%
<= 1 year 53 (72%) 87% 80% 86% 84%
20 μm >= 5 years 45 (73%) 78% 90% 93% 81%
<= 1 year 53 (92%) 100% 91% 94% 93%
40 μm >= 5 years 45 (82%) 93% 86% 88% 83%
<= 1 year 53 (92%) 100% 96% 90% 93%
Samples eligible for downstream analyses have sufficient quantity and quality of input DNA. For methylation, only samples with sufficient DNA (over 63 ACTB
copies) are considered. Samples are labeled methylated when exceeding .27, 26.8 or 25.8 copies for GSTP1, APC and RASSF1 respectively, as preliminary
determined based on the results of Figure 1F, optimizing for maximal correlation with the presence of cancer foci. The percentage of correctly analyzable samples
is the combination of sufficient input DNA and detectability of methylation signals of either assay, when methylation should have been detected.
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multiple cancer types, including prostate cancer, this
phenomenon is present as a field effect, offering the pos-
sibility to detect aberrant methylation at a distance from
the actual tumor [14], and is currently used to develop
an assay to improve upon standard histopathology in
prostate cancer detection.
Several genes have been described as methylation bio-
markers for prostate cancer, including the three genes that
are the subject of this analysis. GSTP1 is likely the most
studied epigenetic lesion in relation to prostate cancer
[26–28]. In addition, the gene is also of potential use as a
screening marker in non-invasive samples such as urine
and blood [29]. APC and RASSF1 have also been described
as prostate cancer markers with important roles in detect-
ing the epigenetic field effect surrounding cancer foci
[14,27]. In this paper, a multiplex assay detecting methyla-
tion of GSTP1, APC and RASSF1 has been developed and
evaluated. The transition of singleplex to multiplex should
lead to a decreased variance and restrain potential sources
of error. In addition, it allows smaller sample quantities to
be used as input for the assay, which is critical given that
often limited cancer is found in needle biopsy tissue.
Multiplexing the three epigenetic assays and the ACTB
control gene into one reaction leads to copy number and
methylation ratio alterations relative to individual singleplex
assays. The use of different fluorophores for the individual
primers is most likely the main reason, although altered
thermodynamics and PCR efficiencies cannot be com-
pletely excluded. The effect appears to be consistent for
each individual assay, but not between different assays
(Figure 1). Although this changes the interpretation of
the calculated methylation ratios, the final outcome, i.e.
detection or absence of methylation, should be deter-
mined with the same accuracy as with individual single-
plex assays. Although only a small test cohort was
available for verification, similar correlations between
methylation and the presence of cancer foci wereobtained. A small decrease in MCC was observed for
APC and RASSF1. However, it can be argued that due
to the consistency in copy number changes, the ratios
should also be altered in a consistent manner. This sup-
ports the belief that the observed, minor decreases in
correlation are random effects, errors that are not linked
to the transition of singleplex to multiplex.
A typical biopsy tissue core using an 18-gauge needle
produces a cylindrical mass of approximately 1 mm
thick. A variable amount of tissue is cut from the FFPE
block for analysis, especially if an atypical focus is noted
and recuts are performed. This leaves an uneven amount
of tissue remaining within the paraffin block. Thus, the
smaller the tissue requirement to do further testing, in-
cluding analytical, molecular analyses, the better.
The assays were initially developed using prostatec-
tomy samples and 40 microns of biopsy tissue from
FFPE blocks. However, such amounts of tissue are not
always readily available for confirmatory assays, e.g. con-
firming a negative histology outcome or detecting occult
cancer. Therefore, it was tested whether the multiplex
assay could generate the same methylation outcome in
smaller biopsies of 20 or even 10 μm. The smallest biopsy
volume clearly possessed a suboptimal performance, where
methylation was more often missed due to erroneous sam-
ple localization (Table 1). The minimally required amount
of input DNA for reliable, repeatable detection of methyla-
tion was not observed for the 10 μm, as opposed to 20 and
40 μm samples (Figure 2 and Table 1). The occasional lack
of detecting methylation in cancer-positive samples from
20 μm biopsies could relate to tissue sampling errors, older
samples or lack of sufficient input. Additionally, not all tis-
sue sections may have methylated promoter regions for
any of the 3 genes. In general, the intuitive rule that more
recent, larger samples are better for Q-MSP analysis was
proven true (Table 1). Because 20-micron samples pre-
served in FFPE for up to 5 or 6 years seem to be border-
line, requiring more DNA for testing seems reasonable
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down to 20 micron provide sufficient input DNA up to an
age of 6 years. For recently archived tissue, up to one year,
20-micron samples appear as adequate as their 40-micron
counterparts.
A 2-fold dilution experiment ranging from 512 to 2
copies of the plasmid vector used for the multiplex assay
was set up with 24 repeats per dilution factor (data not
shown) to determine the limit of detection and analytical
sensitivity of the assay. As little as 16 methylated copies
of APC and GSTP1 and 32 copies of RASSF1 could be
detected reliably, i.e. in more than 95% of the samples.
This illustrates the high analytical sensitive of an MSP-
based epigenetic assay.
In conclusion, an epigenetic, confirmatory multiplex
assay for detecting the presence of prostate cancer cells
missed by histology has been further developed. It per-
formed similar relative to the individual singleplex assays
for the most important test trait, biomarker gene methy-
lation status. Epigenetic testing can be executed in an
accurate and reliable manner in FFPE core tissue biop-
sies, with as little as 20 μm of sample volume.
Methods
Thirty tissue samples for the multiplex versus singleplex ex-
periment were obtained during routine prostatectomy as
the standard care for 7 patients at the Institut de Pathologie
Génétique (IPG, Gosselies, Belgium) and approved by the
ethical committees of IPG Gosselies and CHU (Sart-
Tilman, Belgium). Since this is a non-interventional,
retrospective, subject-anonymized study, written patient
consent was not required by the ethics committees. In
addition, 12 cancer-negative BPH (benign prostatic hyper-
plasia) TURP (transurethral resection of the prostate) sam-
ples were obtained from a commercial supplier (Biona
Center for Biotechnology, Cluj-Napoca, Romania).
Samples for the tissue minimization experiment were
obtained from 51 patients, all with Gleason sum 6 (3+3)
adenocarcinoma of the prostate, undergoing routine pros-
tate biopsy procedures at The Johns Hopkins Medical Cen-
ter. Testing of these anonymized samples was approved by
the IRB at the Johns Hopkins Medical Institutions. Two
sets of recent and older specimens were compared, 27
patients’ samples were obtained in 2011, 16 in 2005 and 8
in 2006. For 46 patients multiple, up to 4, cores were avail-
able for testing, totaling to 102 unique biopsy samples to be
analyzed. Whenever possible, seven 10 micron sections
were taken from each of these FFPE blocks, and randomly
divided as one tissue biopsy of 40 μm, one of 20 μm and
one of 10 μm volume of test tissue.
Samples from all cohorts were prepared identically,
i.e. cells were scraped from the biopsy slides, followed by
deparaffinization (Deparaffinization Solution, Qiagen) and
cell lysis (EpiTect Plus FFPE bisulfite kit, Qiagen). After theDNA was isolated, it was bisulfite treated (EpiTect Plus
FFPE bisulfite kit, Qiagen), and split into two equivalent
replicates for real-time Q-MSP (quantitative methylation
specific PCR) analysis (QuantiTect Multiplex NoROX kit,
Qiagen).
Epigenetic profiling of prostate biopsy samples was
based on a modified, quantitative version of the original
MSP protocol [30]. In short, a molecular-beacon-based
approach was used to detect methylated copies of
GSTP1, APC and RASSF1, either as three separate reac-
tions or multiplexed into one. For each reaction, ACTB
was used as a control (Additional file 1: Table S1).
A standard curve was included in each run for quanti-
tative purposes. To this end, custom plasmid vectors
were ordered (IDT, Iowa, USA) and a stock solution
containing 800.000 copies per 5 μl was prepared. A serial
10-fold dilution was made down to 8 copies per 5 μl. All
6 standards were included in each PCR run. The vectors
contained either the relevant fragment of one gene (sin-
gleplex reactions) or all relevant fragments of each one
of the 4 genes (multiplex reactions). The standard curves
allowed copy number calculations to be performed for
each run. Normalized methylation ratios were calculated
by dividing the detected amount of methylated copies by
the amount of detected ACTB copies and multiplying
this result by 1000 for interpretability.
All analyses were performed using R and BioConduc-
tor, including the ROCR package [31,32].
Additional file
Additional file 1: VanNesteLetal_Supplementary_BMCUrol_rev1
contains Additional file 1: Table S1 (primers and beacons) and
Additional file 1: Figure S1 (illustrative ROC curves).
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